GlassScriptPhysician profile
Suprith Badarinath
NPI 1972508356
$2,209.97
in general payments reported to CMS, 2019-2025
36 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $184 · 2021: $530 · 2022: $144 · 2023: $147 · 2024: $421 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $342.45 | 2019-2024 | Padcev |
| Pfizer INC. | $291.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $286.94 | 2019-2025 | |
| Janssen Biotech, INC. | $140.94 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Genmab U.S., INC. | $110.80 | 2024 | Epkinly |
| Foundation Medicine, INC. | $89.02 | 2020-2021 | |
| Taiho Oncology, INC. | $85.79 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $72.21 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $70.50 | 2019-2021 | |
| Genzyme Corporation | $69.23 | 2022-2025 | |
| Exelixis INC. | $68.77 | 2021-2025 | Cabometyx |
| Incyte Corporation | $51.56 | 2019-2020 | |
| Genentech USA, INC. | $50.41 | 2019-2022 | |
| Array Biopharma INC | $45.40 | 2024-2025 | Braftovi, Lorbrena, Tukysa |
| Alexion Pharmaceuticals, INC. | $44.90 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.53 | 2021-2023 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $29.79 | 2019 | |
| Mirati Therapeutics, INC. | $28.82 | 2023-2024 | Krazati |
| Tempus Ai, INC | $27.68 | 2025 | Xt Cdx |
| Tg Therapeutics, INC. | $26.39 | 2021 | |
| Puma Biotechnology, INC. | $24.93 | 2019 | |
| Gilead Sciences, INC. | $24.36 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.50 | 2024 | |
| Intuitive Surgical, INC. | $18.41 | 2024 | |
| Eisai INC. | $16.16 | 2019 | |
| Merck Sharp & Dohme LLC | $15.99 | 2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $15.84 | 2023 | Calquence |
| Cti Biopharma Corp. | $15.38 | 2023 | Vonjo |
| Secura Bio, INC. | $13.95 | 2025 | Copiktra |
| Aurobindo Pharma USA, INC. | $13.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.83 | 2024 | Opdivo |
| Daiichi Sankyo INC. | $13.16 | 2022 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Morphosys, US INC. | $12.43 | 2021 | |
| Lilly USA, LLC | $11.25 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suprith Badarinath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.